Cargando…

Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors

Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8(+) cytotoxic T lymphocyte (CTL). Whether other steps along the PD‐1 signaling pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Zhenzhen, Tian, Yahui, Chen, Zhipeng, Liu, Lu, Zhou, Qian, He, Jingjing, Coleman, James, Dong, Changjiang, Li, Nan, Huang, Junqi, Xu, Chenqi, Zhang, Zhimin, Gao, Song, Zhou, Penghui, Ding, Ke, Chen, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278553/ https://www.ncbi.nlm.nih.gov/pubmed/32391629 http://dx.doi.org/10.15252/emmm.201911571

Ejemplares similares

Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation
por: Patsoukis, Nikolaos, et al.
Publicado: (2020)

Molecular mechanism of SHP2 activation by PD-1 stimulation
por: Marasco, M., et al.
Publicado: (2020)

Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors
por: Toral, Keller J., et al.
Publicado: (2021)

PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
por: Xu, Xiaozheng, et al.
Publicado: (2020)

Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity
por: Chen, Zhipeng, et al.
Publicado: (2020)

SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
por: Christofides, Anthos, et al.
Publicado: (2022)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Li, Zhitao, et al.
Publicado: (2021)

High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer
por: Feng, Hui‐Bo, et al.
Publicado: (2021)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

PD-L1/PD-1: new kid on the “immune metabolic” block
por: Qorraj, Mirjeta, et al.
Publicado: (2017)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
por: Yajuk, Olga, et al.
Publicado: (2021)

PD-1(+) mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
por: Li, Jun, et al.
Publicado: (2022)

Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia
por: Liu, Ben-Long, et al.
Publicado: (2020)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load
por: Zhou, Yajuan, et al.
Publicado: (2017)

Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis
por: Gu, Zikuan, et al.
Publicado: (2022)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
por: Yin, Zi, et al.
Publicado: (2021)

Radiotherapy combined with PD‐1/PD‐L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges
por: Chen, Zi‐Ying, et al.
Publicado: (2022)

PD-1/SHP-2 negatively regulate Tc1/Th1 phenotypic responses and activation of T cells in the tumor microenvironment
por: Li, Jing, et al.
Publicado: (2014)

The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge
por: Li, Chen, et al.
Publicado: (2023)

Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
por: Xue, Song, et al.
Publicado: (2017)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
por: Liu, Xiaoqiang, et al.
Publicado: (2019)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes
por: Zhou, Yajuan, et al.
Publicado: (2017)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

The implication of the PD-1/PD-L1 checkpoint in chronic periodontitis suggests novel therapeutic opportunities with natural products
por: Bailly, Christian
Publicado: (2020)

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
por: Hack, Stephen P., et al.
Publicado: (2020)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export
por: Chen, Fang-Fang, et al.
Publicado: (2020)

Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
por: Mo, Zhongfu, et al.
Publicado: (2016)

Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy
por: Zhou, Yuqing, et al.
Publicado: (2022)

SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells
por: Liu, Zhuqing, et al.
Publicado: (2017)

Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding
por: Shin, Jong, et al.
Publicado: (2021)

Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models
por: Wu, Yinglin, et al.
Publicado: (2022)

New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
por: Dai, Mengyuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_26dokhb229ftsklahghvuupfgh